TITLE

DA-6034, A NEW THERAPEUTIC AGENT OF INFLAMMATORY BOWEL DISEASE

AUTHOR(S)
Shin, C.Y.; Son, M.; Lee, I.K.; Jung, M.Y.; Kim, D.S.; Kim, S.H.; Yoo, M.; Song, I.S.; Kim, W.B.
PUB. DATE
April 2003
SOURCE
Gut;Apr2003 Supplement 1, Vol. 52, pA63
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
DA-6034, 7-carboxymethyloxy-3', 4', 5-trimethoxy flavones, is a synthetic flavonoid known to possess anti-inflammatory activity. In this study, we evaluated the oral therapeutic effect of DA-6034 in four experimental animal models of inflammatory bowel disease (IBD). In acetic acid (4%) induced IBD rat models, prednisolone (1 mg/kg), sulfasalazine (100 mg/kg) and DA-6034 (3 mg/kg) significantly reduced the severity of colitis. Especially, DA-6034 (3 mg/kg) showed more potent effect than other drugs in macroscopic lesion score, tn trinitrobenzene sulfonic acid (TNBS) induced IBD rat models, prednisolone (3.0mg/kg) or DA-6034 (3.0mg/kg) inhibited the colonic mucosal damage. DA-6034 (3.0mg/kg) significantly decreased the prostaglandin E[sub 2] levels, leukotriene B[sub 4] levels and myeloperoxidase activity at 7 day as compared with control. In Dextran sulfate sodium (DSS)-induced colitis mice, DA-6034 reduced the colitis index-diarrhea incidence, body weight, mortality, and intestinal gross lesion. In HLA-B27 transgenic rats, DA-6034 (3 mg/kg) and prednisolone (0.5 mg/kg) were treated orally twice daily for 6 weeks. The HLA-B27 transgenic rats showed only mild colitis, compared with the chemical-induced colitis models. DA-6034 ameliorated the loose stool and decreased microscopic damage, which is the important indicator of this model. In conclusion, DA-6034 attenuated the macroscopic and histological damages of the colon in all four experimental models of IBD, which suggest that DA-6034 could be a promising drug in the treatment of IBD and we will set out clinical Phase I study of DA-6034 in next year.
ACCESSION #
9747716

 

Related Articles

  • Do Non-steroidal Anti-inflammatory Drugs Cause Exacerbations of Inflammatory Bowel Disease? Feagins, Linda A.; Cryer, Byron L. // Digestive Diseases & Sciences;Feb2010, Vol. 55 Issue 2, p226 

    The safety of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with inflammatory bowel disease (IBD) remains unclear. This report discusses potential mechanisms whereby NSAIDs might exacerbate IBD and reviews the available clinical data on the role of NSAIDs in causing exacerbations of...

  • Kinases as Drug Targets in Inflammation: In Vitro and In Vivo Target Validation and Expression Profiling. Clarissa Gust, Tatjana; Bonin, Arne v. // Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry;Feb2007, Vol. 6 Issue 1, p19 

    Inflammation seems to be at the beginning of the majority of chronic diseases, and major efforts are dedicated to the development of anti-inflammatory drugs. Chronic inflammatory diseases, such as psoriatic arthritis, rheumatoid arthritis, inflammatory bowel disease and asthma, are diseases that...

  • New Approaches to the Treatment of Inflammatory Disorders Small molecule inhibitors of p38 MAP kinase. Peifer, Christian; Wagner, Gerd; Laufer, Stefan // Current Topics in Medicinal Chemistry;Jan2006, Vol. 6 Issue 2, p113 

    The therapy of chronic inflammatory diseases like rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) has recently been enriched by the successful launch of the anti-cytokine biologicals Etanercept (tumor necrosis factor (TNF) receptor-p75 Fc fusion protein), Infliximab (chimeric...

  • Recurrent Acute Pericarditis Induced by 5-aminosalicylates in a Patient with Inflammatory Bowel Disease. A. Ra Choi; Mi Na Kim; Ji Hoon Lee; Yong Kang Lee; Yoon Hea Park; Hye Sun Shin; Tak Geun Oh; Hee Jin Park; Min Suk Park; Seungtaek Lim; Soo Jung Park; Sung Pil Hong; Tae Il Kim; Won Ho Kim; Jae Hee Cheon // Intestinal Research;2012, Vol. 10 Issue 3, p289 

    Inflammatory bowel disease (IBD) is an idiopathic chronic inflammation of the intestines. IBD treatment may require anti-inflammatory agents such as sulfasalazine or 5-aminosalicylate (5-ASA) and immunomodulators to control the symptoms. However, these agents have a variety of common adverse...

  • The Gastrointestinal Safety and Effect on Disease Activity of Etoricoxib, a Selective Cox-2 Inhibitor in Inflammatory Bowel Diseases. El Miedany, Yasser; Youssef, Sally; Ahmed, Ihab; El Gaafary, Maha // American Journal of Gastroenterology;Feb2006, Vol. 101 Issue 2, p311 

    BACKGROUND: While traditional nonsteroidal antiinflammatory drugs (t-NSAIDs) are relatively contraindicated in patients with inflammatory bowel disease (IBD) for fear of disease aggravation, controlled clinical trials showed that cyclo-oxygenase-2 inhibitors have fewer gastrointestinal side...

  • Biological Variability and Targeted Delivery of Therapeutics for Inflammatory Bowel Diseases: An In Silico Approach. Haddish-Berhane, Nahor; Farhadi, Ashkan; Nyquist, Chell; Haghighi, Kamyar; Keshavarzian, Ali // Inflammation & Allergy - Drug Targets;Jan2007, Vol. 6 Issue 1, p47 

    Existing treatments of IBD adopt targeted oral drug delivery route for delivering bioactive agents more efficiently and with fewer side effects. However, the complex and dynamic luminal environment of the GIT and major intra/ inter patient variability greatly affects treatment, resulting in...

  • Do inflammatory bowel disease therapies cause cancer? Balzola, Federico; Cullen, Garret; Hoentjen, Frank; Ho, Gwo-Tzer; Russell, Richard // Inflammatory Bowel Disease Monitor;2013, Vol. 13 Issue 4, p164 

    The article discusses the side effect of thiopurines or anti-tumor necrosis factor agents to treat patients with inflammatory bowel diseases (IBD). It examines the role of anti-inflammatory drugs to reduce the risk of cancer associated with the risk of neoplasia and the duration of inflammation....

  • Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Zhen-Zhong Xu; Ling Zhang; Tong Liu; Jong Yeon Park; Temugin Berta; Rong Yang; Serhan, Charles N.; Ru-Rong Ji // Nature Medicine;May2010, Vol. 16 Issue 5, p592 

    Inflammatory pain, such as arthritis pain, is a growing health problem. Inflammatory pain is generally treated with opioids and cyclooxygenase (COX) inhibitors, but both are limited by side effects. Recently, resolvins, a unique family of lipid mediators, including RvE1 and RvD1 derived from...

  • IL-10 Counteracts Proinflammatory Mediator Evoked Oxidative Stress in Caco-2 Cells. Latorre, Eva; Matheus, Nyurky; Layunta, Elena; Alcalde, Ana Isabel; Mesonero, José Emilio // Mediators of Inflammation;2014, p1 

    Oxidative stress is thought to play a key role in the development of intestinal damage in intestinal inflammatory diseases. Several molecules are involved in the intestinal inflammation, either as pro- or anti-inflammatory factors;however, their effects on intestinal oxidative stress seem to be...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics